MYRX (Myrexis) EPS (Basic): $-0.40 (TTM As of Jun. 2013)


What is Myrexis EPS (Basic)?

Myrexis MYRX -11.11% EPS (Basic) is $-0.40 as of Jun. 2013.

Myrexis's basic earnings per share (Basic EPS) for the three months ended in Jun. 2013 was $0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2013 was $-0.40.

Myrexis's EPS (Diluted) for the three months ended in Jun. 2013 was $0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2013 was $-0.40.

Myrexis's EPS without NRI for the three months ended in Jun. 2013 was $0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2013 was -0.41.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Myrexis  (OTCPK:MYRX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Myrexis EPS (Basic) Related Terms

Myrexis EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Myrexis's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myrexis EPS (Basic) Chart

Myrexis Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13
EPS (Basic)
Get a 7-Day Free Trial -2.43 -1.91 -1.52 -1.18 -0.39

Myrexis Quarterly Data
Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.13 -0.18 -0.11 0.02

Myrexis EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Myrexis's Basic EPS for the fiscal year that ended in Jun. 2013 is calculated as

Basic EPS (A: Jun. 2013 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.621-0)/29.508
=-0.39

Myrexis's Basic EPS for the quarter that ended in Jun. 2013 is calculated as

Basic EPS (Q: Jun. 2013 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.151-0)/34.461
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.40 mean?
Myrexis (MYRX) has a EPS (Basic) of $-0.40 as of Jun. 2013. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Myrexis and its competitors.
Is Myrexis' EPS (Basic) too high?
Myrexis' current EPS (Basic) is $-0.40.
How does Myrexis' EPS (Basic) compare to MGHL and NTWN?
Myrexis' EPS (Basic) of $-0.40 can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Diversified Financial Services company?
A good EPS (Basic) depends on the Diversified Financial Services industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Myrexis and its competitors. Myrexis's current EPS (Basic) is $-0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myrexis stock overvalued right now?
Myrexis (MYRX) has a current EPS (Basic) of $-0.40. The current EPS (Basic) is $-0.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Myrexis (MYRX), the current EPS (Basic) is $-0.40 as of Jun. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Myrexis Business Description

Address 600 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.